Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials
Changes in laboratory parameters at M1 could potentially be used to assess whether tofacitinib therapy will be effective at M3; however, further investigation is needed.
Authors
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Shigeyuki Toyoizumi (ORCID: https://orcid.org/0000-0002-7011-5263)
- Hisashi Yamanaka (ORCID: https://orcid.org/0000-0001-8453-6731)
- Tomohiro Hirose (ORCID: https://orcid.org/0000-0002-9569-6834)
- Tsutomu Takeuchi (ORCID: https://orcid.org/0000-0003-1111-8218)
Institutions
- University of Occupational and Environmental Health Japan (JP)
- Keio University (JP)
- Pfizer (Japan) (JP)
- Sanno Medical Center (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1093/mr/roae109
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.94